The FDA panel will vote Friday afternoon about whether to recommend the Pfizer-BioNTech booster for people 16 and older at least six months after their initial vaccination.
Related posts:
FDA fights for independence in Trump administration’s final days
Biden dresses down his Covid team over plans to speed vaccinations
States struggle for control of chaotic vaccine rollout
Trump misses 20 million Covid shot target
White House weighs sending states’ unused vaccine doses abroad — before they expire
Sweeney, Coughlin introduce new bill to end health emergency, limit Murphy’s powers
Black Americans lag in Biden’s vaccine equity push
Fauci: ‘I don’t think we’re going to see lockdowns’
FDA targets early September for approving Pfizer’s Covid-19 vaccine
No ‘clear’ messaging about pandemic from Biden and Trump administrations, Maryland’s governor says
WHO says measures used against Delta should work for Omicron
Judge blocks Biden’s vaccine mandate for federal contractors
